Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : InvestRight - Short Term Trading St -- Ignore unavailable to you. Want to Upgrade?

To: mike mulhearn who wrote (128)	9/14/1998 12:41:00 AM
From: CENTrader	Read Replies (1) \| Respond to of 939

Mike, Exten is proposing to GIVE the device away to hospitals, once it's approved, so as to compete with other liver machine companies. Mgt. claims the Sybiol machine is more efficient & cheaper to use than their competitors. The bulk of the profits are in the disposable contents of the machine, where there is a large profit margin. But....first, they need to find some cash to keep this baby afloat. They need about $200k just to complete preclinicals, and $3-5 Million more to complete the clinical trials. They have been looking for funding for quite some time, and it's a longshot that they will find it in time to compete. (Hence the .03 price) There are a number of other "affluent" companies way ahead of them in the trials process. Of course, I do hope they find the money, SOON! This industry has a huge profit potential, estimated @ approx. 2 Billion/yr worldwide. -Bill ^$^